Cargando…
Advances in the application of 3D tumor models in precision oncology and drug screening
Traditional tumor models cannot perfectly simulate the real state of tumors in vivo, resulting in the termination of many clinical trials. 3D tumor models’ technology provides new in vitro models that bridge the gap between in vitro and in vivo findings, and organoids maintain the properties of the...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9555934/ https://www.ncbi.nlm.nih.gov/pubmed/36246388 http://dx.doi.org/10.3389/fbioe.2022.1021966 |
_version_ | 1784806960222175232 |
---|---|
author | Guan, Xiaoyong Huang, Shigao |
author_facet | Guan, Xiaoyong Huang, Shigao |
author_sort | Guan, Xiaoyong |
collection | PubMed |
description | Traditional tumor models cannot perfectly simulate the real state of tumors in vivo, resulting in the termination of many clinical trials. 3D tumor models’ technology provides new in vitro models that bridge the gap between in vitro and in vivo findings, and organoids maintain the properties of the original tissue over a long period of culture, which enables extensive research in this area. In addition, they can be used as a substitute for animal and in vitro models, and organoids can be established from patients’ normal and malignant tissues, with unique advantages in clinical drug development and in guiding individualized therapies. 3D tumor models also provide a promising platform for high-throughput research, drug and toxicity testing, disease modeling, and regenerative medicine. This report summarizes the 3D tumor model, including evidence regarding the 3D tumor cell culture model, 3D tumor slice model, and organoid culture model. In addition, it provides evidence regarding the application of 3D tumor organoid models in precision oncology and drug screening. The aim of this report is to elucidate the value of 3D tumor models in cancer research and provide a preclinical reference for the precise treatment of cancer patients. |
format | Online Article Text |
id | pubmed-9555934 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-95559342022-10-13 Advances in the application of 3D tumor models in precision oncology and drug screening Guan, Xiaoyong Huang, Shigao Front Bioeng Biotechnol Bioengineering and Biotechnology Traditional tumor models cannot perfectly simulate the real state of tumors in vivo, resulting in the termination of many clinical trials. 3D tumor models’ technology provides new in vitro models that bridge the gap between in vitro and in vivo findings, and organoids maintain the properties of the original tissue over a long period of culture, which enables extensive research in this area. In addition, they can be used as a substitute for animal and in vitro models, and organoids can be established from patients’ normal and malignant tissues, with unique advantages in clinical drug development and in guiding individualized therapies. 3D tumor models also provide a promising platform for high-throughput research, drug and toxicity testing, disease modeling, and regenerative medicine. This report summarizes the 3D tumor model, including evidence regarding the 3D tumor cell culture model, 3D tumor slice model, and organoid culture model. In addition, it provides evidence regarding the application of 3D tumor organoid models in precision oncology and drug screening. The aim of this report is to elucidate the value of 3D tumor models in cancer research and provide a preclinical reference for the precise treatment of cancer patients. Frontiers Media S.A. 2022-09-28 /pmc/articles/PMC9555934/ /pubmed/36246388 http://dx.doi.org/10.3389/fbioe.2022.1021966 Text en Copyright © 2022 Guan and Huang. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Bioengineering and Biotechnology Guan, Xiaoyong Huang, Shigao Advances in the application of 3D tumor models in precision oncology and drug screening |
title | Advances in the application of 3D tumor models in precision oncology and drug screening |
title_full | Advances in the application of 3D tumor models in precision oncology and drug screening |
title_fullStr | Advances in the application of 3D tumor models in precision oncology and drug screening |
title_full_unstemmed | Advances in the application of 3D tumor models in precision oncology and drug screening |
title_short | Advances in the application of 3D tumor models in precision oncology and drug screening |
title_sort | advances in the application of 3d tumor models in precision oncology and drug screening |
topic | Bioengineering and Biotechnology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9555934/ https://www.ncbi.nlm.nih.gov/pubmed/36246388 http://dx.doi.org/10.3389/fbioe.2022.1021966 |
work_keys_str_mv | AT guanxiaoyong advancesintheapplicationof3dtumormodelsinprecisiononcologyanddrugscreening AT huangshigao advancesintheapplicationof3dtumormodelsinprecisiononcologyanddrugscreening |